Evidence map›Paper›PMID 38408440›Full record

Trial reportActa haematologica2024

Zanubrutinib plus Cytarabine in Patients with Refractory/Relapsed Primary Central Nervous System Lymphoma.

Zhiguang Lin, Jingjing Ma, Yan Ma, Qing Li, Hui Kang, Mengxue Zhang, Bobin Chen

Open access · greenAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Acta haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Observational
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Zhiguang LinDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, China, zhiguang_lin@163.com.
Jingjing MaDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
Yan MaDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
Qing LiDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
Hui KangDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
Mengxue ZhangDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
Bobin ChenDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
Fudan University · CNHuashan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPrimary central nervous system lymphoma (PCNSL) is a rare subtype of aggressive extranodal non-Hodgkin lymphoma. Currently, there is no standard of care for the treatment of refractory or relapsed PCNSL (r/r PCNSL). We conducted a prospective single-arm phase II study to evaluate zanubrutinib plus cytarabine for r/r PCNSL.

methodsUsing Simon's two-stage design, we analyzed 34 patients who received high-dose cytarabine (3.0 g/m2 once daily) for 2 days and zanubrutinib (160 mg twice daily) for 21 days each cycle for up to 6 cycles. The study was registered at <ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn" xmlns:xlink="http://www.w3.org/1999/xlink">www.chictr.org.cn</ext-link> as #ChiCTR2000039229.

resultsThe median follow-up was 19 months. The overall response rate was 64.7% (95% confidence interval [CI], 47.9-78.5%) with a complete remission or unconfirmed complete remission rate of 47.1% (16/34) and a partial remission rate of 17.6% (6/34). The median progression-free survival was 4.5 months (95% CI, 1.5-9.4), and the median OS was 18 months (95% CI, 9.5 to not estimable). The median duration of the response was 9 months (95% CI, 3.2 to not estimable). The most common treatment-emergent adverse events were thrombocytopenia (55.9%). No treatment-related death occurred.

conclusionZanubrutinib and cytarabine showed efficacy in r/r PCNSL with an acceptable safety profile.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsCytarabinePyrazolesPyrimidinesAdultAgedFemaleHumansLymphoma, Non-HodgkinMaleMiddle AgedPiperidinesProspective StudiesCytarabinePiperidinesPyrazolesPyrimidineszanubrutinibBruton’s tyrosine kinase inhibitorCytarabineDiffuse large B-cell lymphomaPrimary central nervous system lymphomaZanubrutinib

Identifiers

PMID38408440
PMCPMC11441377
OpenAlexW4392353268

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.